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Abstract 
In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 µg 
ethinylestradiol and 3 mg drospirenone (Yasmin™) with a reference preparation containing 30 µg 
ethinylestradiol and 150 µg desogestrel (Marvelon™) on variables of carbohydrate metabolism by means of oral 
glucose tolerance tests at baseline and in the 6th and 13th treatment cycle. The mean levels of fasting glucose 
and insulin were similar at baseline and after 13 treatment cycles, whereas C-peptide and free fatty acid levels 
decreased slightly in both groups. All blood glucose and insulin values measured in the oral glucose tolerance 
tests were within normal ranges, despite a slight increase in the mean areas under the curves of 0-3 h [AUCs (0-3 
h)] of both variables from baseline to treatment cycle 13. Differences between both treatments were not 
statistically significant. The mean AUCs (0-3 h) for C-peptide were not markedly changed in any treatment 
group. Free fatty acid levels decreased by 42% in the drospirenone group and increased by 48.9% in the 
desogestrel group, in terms of means of individual changes. Both preparations were well tolerated and equally 
efficacious regarding contraception and cycle control. The mean body weight was slightly decreased in most 
cycles during treatment with the drospirenone combination, as compared to baseline, while it was slightly 
increased versus baseline in all cycles during treatment with the desogestrel combination. The combination with 
drospirenone had less impact on blood pressure than the combination with desogestrel. In conclusion, Yasmin, a 
combined low-dose oral contraceptive with 30 µg ethinylestradiol and 3 mg of the novel progestogen 
drospirenone, as well as the reference Marvelon, containing 30 µg ethinylestradiol and 150 µg desogestrel had 
little impact on carbohydrate metabolism when used for 1 year. The observed changes were small and not 
suggestive of a clinically relevant deterioration of carbohydrate metabolism. 
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1. INTRODUCTION 
Oral contraceptives (OCs) are now used for more than 40 years and have been proved to be a highly efficacious 
and safe method for contraception. The hormonal components of OCs, estrogens (usually ethinylestradiol) and 
progestins, are known to have various metabolic effects, including effects on carbohydrate metabolism. 
Therefore, international guidelines, e.g., the "Note for guidance on clinical investigation of steroid contraceptives 
in women" [1], recommend to investigate the influence of OCs on variables of carbohydrate metabolism for 
safety reasons. Although slight decreases in glucose tolerance and increases in insulin resistance have been 
reported for some OCs by means of oral or intravenous glucose tolerance tests (oGTTs, ivGTTs) or glucose 
clamps [2,3], evidence for an increased risk to develop manifest diabetes has never been provided. However, a 
further investigation of the long-term consequences of OC use on carbohydrate metabolism is important because 
any chronic—even mild—hyperglycemia and/or hyperinsulinemia in the fasting state as well as during a glucose 
load may contribute to ischemic vascular diseases [4-8] and to the metabolic syndrome (or Syndrome X) 
described by Reaven [9]. 
Although the specific contributions of the estrogen and the progestin to the metabolic effects of OCs are not fully 
understood, it is evident that the dose of ethinylestradiol (EE) and the dose and type of the progestin—
particularly its androgenic properties—affect the metabolic influence of OCs [10]. In this respect, the novel 
progestin drospirenone (DRSP), a 17-α-spirolactone derivative, is particularly interesting because of its unique 
pharmacological profile with antiandrogenic and antimineralocorticoid activity in addition to its potent 
progestogenic activity [11-13]. The antimineralocorticoid activity, which has not yet been described for any 
other synthetic progestin, may reduce possible water retention in women using OCs [14]. 
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The combination of 3 mg DRSP with 30 µg EE (Yasmin™) was recently approved for marketing as an OC in 
Europe and the US. The preparation is characterized by a high contraceptive efficacy in combination with 
excellent cycle control and a low incidence of adverse effects [15]. In an earlier study, Oelkers et al. [16] 
provided evidence for favorable metabolic effects of the preparations. However, more information is needed in 
order to judge its metabolic impact. 
In the present study, we compared the effects of Yasmin with the marketed OC Marvelon™ containing 30 µg EE 
in combination with 150 µg of the 19 Nor-testosterone derivative desogestrel (DSG) on carbohydrate 
metabolism. 
2. MATERIALS AND METHODS 
The study was performed as an open-label, randomized, prospective study at one center in Belgium (Centre 
Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman-B.35-4000 Liège 1-Belgique) from 
January 1994 to June 1997. We compared Yasmin (Schering AG, Berlin, Germany) containing 30 µg EE and 3 
mg DRSP with Marvelon (Organon, Oss, The Netherlands) containing 30 µg EE and 150 µg DSG, as a reference 
preparation. The study protocol was approved by the appropriate ethics committee before the study started. 
We recruited a total of 60 healthy women aged 18 to 28 years. A total of 54 volunteers started the study 
medication (27 in each treatment group) and were included in the full analysis set for the safety evaluation. Of 
these, 50 (25 in each group) were included in the per protocol analysis for the efficacy evaluation. Four 
volunteers were excluded from the per protocol analysis due to premature discontinuation of the study 
medication or other protocol deviations. 
The women's wish for contraception for at least 13 cycles of 28 days each was a prerequisite for their 
participation in the study. New OC users as well as women who wanted to change their OC (switchers) were 
included in the study. Switchers were required to have at least two OC-free cycles, one wash-out cycle and one 
pretreatment cycle, before they started to take the study medication. The exclusion criteria were similar to the 
contraindications for OC use. Further exclusion criteria were the use of parenteral depot-contraceptives in the 
last 6 months before the start of the study, specified coexisting diseases such as diabetes or endocrinopathies, the 
intake of medications interfering with lipid or carbohydrate metabolism, diagnostically unclassified genital 
bleeding and a history of migraine accompanying menstruation. Smoking of up to 10 cigarettes per day was 
allowed. Each volunteer had a thorough medical and gynecological examination, including a cervical cytology 
examination using the Papanicolau method and a pregnancy test, before start of treatment. All volunteers gave 
their informed consent prior to participation. 
The volunteers were randomized to treatment with either Yasmin or Marvelon. The first tablet was to be taken 
on the first day of withdrawal bleeding. A 28-day treatment cycle consisted of 21 days with tablet intake 
followed by 7 days without intake. The treatment period lasted for 13 consecutive cycles, 28 days each. The 
study medications were supplied in calendar packs. When the scheduled intake time was missed, the women 
were to take the tablets until up to 12 h after the scheduled time. All deviations from the scheduled intake times 
had to be recorded in a diary. 
The absolute change of the natural logarithm of the area under the curve (AUC) for glucose and insulin and the 
relative change of the lipid variables HDL-, HDL2- (high-density lipoproteins), and LDL-cholesterol (low-
density lipoprotein) from pretreatment to treatment cycle 13 were the target variables in the study. Here we only 
report the results of the carbohydrate variables. The lipid results will be reported separately. 
The laboratory samples were analyzed by two different laboratories at the University Hospital Center, Liège, 
Belgium. Only generally accepted methods were used for the laboratory analyses. Blood glucose was measured 
by the glucose oxidase method adapted to the Auto-Analyzer (Esat 6660; Eppendorf, Germany). Plasma insulin 
(immunoreactive insulin) was measured (in duplicate) by a modified double-antibody radioimmunoassay 
according to Hales and Randle [17] with a filtration instead of centrifugation [intra-assay coefficient of variation 
(CV) = 5.5%; inter-assay CV = 8.7%]. Plasma C-peptide was measured (in duplicate) by a radioimmunoassay 
according to Heding [18] (intra-assay CV = 3.1%; inter-assay CV = 10.8%). Plasma free fatty acids were 
measured by an enzymatic method [19] (intra-assay CV = 3.1%; inter-assay CV = 3.4%). 
The 75-g-standardized oGTTs were carried out at baseline (during the last 7 days of the pretreatment cycle) and 
in treatment cycles 6 and 13 (on days 15-21 of the respective cycles). The volunteers were to eat a standard diet 
throughout the study with a carbohydrate intake of at least 300 g per day (total diet: 2500 kcal). During the last 3 
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days before the tests, strenuous exercise was not allowed. On the day of the test, 75 g glucose was administered 
in 300 mL water. The influence of the study treatments on carbohydrate metabolism was assessed by 
measurements of plasma glucose, insulin, C-peptide and free fatty acid levels. Blood samples were taken with a 
flexible catheter inserted into a superficial forearm vein at a fasting state before glucose was administered 
(together with the samples required for general clinical chemical variables) and in 30-min intervals for 3 h 
thereafter. 
The patients' weight was determined every other day. The blood pressure was measured on all study visits. 
Adverse events, concomitant medication usage and treatment compliance, including a record of intake errors, 
and cycle control patterns, were recorded from the volunteers' diaries and the results of general questioning of 
the volunteers by the investigators. In the follow-up period, the volunteers were asked again about their general 
health during treatment and medical and gynecological examinations, including cervical cytology and routine 
laboratory examinations, were repeated. 
2.1. Statistical methods 
Statistical analyses were performed for both the full analysis and the per protocol set. All randomized volunteers 
who took at least one tablet of the study medication were included in the full analysis set. The per protocol set 
consisted of volunteers without major protocol deviations able to affect the target variables. 
The absolute changes of the natural logarithm of the AUC for glucose and insulin from pretreatment to treatment 
cycle 13 were the target variables in the study. The AUCs were determined using the trapezoidal rule. The 
absolute changes of the natural logarithms of the AUCs were calculated as: natural logarithm of the value 
measured in cycle 13 minus natural logarithm of the value measured in pretreatment cycle. 
For each target variable, the null hypothesis, which stated that the mean values were equal in both treatment 
groups, was tested against its alternative, which stated that the mean values in both treatment groups were not 
equal, using the two-sided t-test for two independent samples. The significance level α of 5% for these tests was 
not adjusted for multiple testing as appropriate for exploratory analyses. 
Table 1: Demographic characteristics at baseline 
 DRSP 
(n = 25) 
DSG 
(n = 25) 
Mean age (years) ± SD 21.5 ± 2.5 21.2 ± 1.8 
Range 18-28 18-25 
Mean weight (kg) ± SD 55.2 ± 6.3 59.8 ± 6.7 
Range 41-69 51-72 
Mean height (cm) ± SD 165.2 ± 5.8 165.0 ± 5.2
Range 157-179 156-176 
Mean Body Mass Index (kg/m2) ± SD 20.2 ± 2.1 21.9 ± 2.0 
Range 16.6-25.2 19.3-25.8 
Prevalence of smoking (% of volunteers) 16 28 
Prior use of OCs (% of volunteers) 77.7 66.6 
Volunteers with regular cycles (%) 100 100 
3. RESULTS 
3.1. Study population 
A total of 63 volunteers were screened, 60 were randomized. Of these, 54 volunteers, i.e., 27 in the DSG group 
(Marvelon) and 27 in the DRSP group (Yasmin) started treatment. Fifty (25 in each group) had no major 
protocol violations and were included in the per protocol set. The demographic characteristics of both groups at 
baseline were well matched with the exception of body weight. The mean body weight was—by chance—4.6 kg 
higher in the DSG group than in the DRSP group (see Table 1). 
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3.2. Carbohydrate metabolism 
3.2.1. Fasting levels 
As shown in Table 2, the mean values for fasting glucose and insulin remained almost unchanged from baseline 
to cycle 6 and 13 in both treatment groups. Fasting C-peptide levels decreased from baseline to cycle 13 by -3.4 
µmol/L in the DRSP group and by -17.8 µmol/L in the DSG group. Free fatty acid levels decreased by an 
average of -48.8 µEq/L in the DSG group compared to -6.6 µEq/L in the DRSP group. 
Table 2: Fasting plasma levels of glucose, insulin, C-peptide and FFA (mean ± SD) 
 Unit Baseline Cycle 6 Cycle 13 Absolute change baseline to 
cycle 13 
  DRSP DSG DRSP DSG DRSP DSG DRSP DSG 
Glucose mg/dL 81.5 ± 10.4 82.0 ± 8.6 80.4 ± 6.8 78.7 ± 8.6 81.2 ± 7.8 81.2 ±7.7 -0.32 ± 11.6 -0.88 ± 9.38
Insulin µU/mL 7.2 ± 5.1 6.2 ± 2.9 8.3 ± 5.5 6.8 ± 4.1 5.6 ± 4.1 6.5 ± 4.9 -1.5 ± 5.5 0.36 ± 4.8 
C-peptide µmol/L 563 ± 215 555 ± 105 619 ± 164 556 ± 153 559 ± 142 537 ± 127 -3.4 ± 184 -17.8 ± 167 
Free fatty acids µEq/L 670 ± 294 712 ± 274 679 ± 210 717 ± 264 621 ± 230 705 ± 225 -48.8 ± 290 -6.63 ± 258 
3.2.2. oGTT 
The mean levels of glucose, insulin, C-peptide and free fatty acids (FFA) in the oGTT at baseline and at cycles 6 
and 13 are shown in Fig. 1 for the DRSP group and in Fig. 2 for the DSG group. Table 3 summarizes the AUCs 
and their absolute changes from baseline to cycle 13. 
Fig. 1: Concentration curves of glucose, insulin, C-Peptide and FFA (means) assessed sequentially during 
OGTT before (baseline) and during use (6 and 12 cycles) of DRSP + EE. 
 
Published in: Contraception (2003), vol. 67, iss. 6, pp. 423-9 
Status: Postprint (Author’s version) 
The mean AUCs (0-3 h) for glucose and insulin increased from baseline to cycle 13. The increases were 
comparable in both treatment groups with 28.7 mg/dL*h in the DRSP and 22.2 mg/dL*h in the DSG group for 
glucose, and 14.3 µU/dL*h in the DRSP and 7.8 µU/dL*h in the DSG group for insulin. Differences between the 
treatment groups were not statistically significant. All individual blood glucose and insulin levels measured at 
any time during the study were within normal ranges and not suggestive of diabetes or impaired glucose 
tolerance in any case [20]. 
The mean AUCs (0-3 h) for C-peptide appeared to be unchanged throughout the treatment period in both groups. 
Free fatty acids decreased by 42 µEq/L*h vs. baseline in the DRSP group as compared to an increase by 48.9 
µEq/L*h in the DSG group (Table 3). 
3.3. Contraceptive efficacy 
None of the randomized volunteers became pregnant during the study. 
3.4. Tolerability 
A total of 18 (33%) of the 54 treated volunteers had a total of 35 adverse events. Most adverse events were 
described as mild and transient. The most common adverse event was breast pain. In each treatment group, one 
serious adverse event (appendectomies) was recorded. Both serious adverse events had no causal relationship to 
the treatments. 
Fig. 2: Concentration curves of glucose, insulin, C-Peptide and FFA (means) assessed sequentially during 
OGTT before (baseline) and during use (6 and 12 cycles) of DSG + EE. 
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Physical and gynecological examinations showed few abnormal findings, all of which were not considered 
treatment-related. 
Blood pressure differences between baseline and cycle 13 were small and not relevant in both groups. The mean 
systolic blood pressure decreased from baseline to cycle 13 by -2.2 mmHg in the DRSP group and increased by 
+2.5 mmHg in the DSG group. The mean diastolic blood pressure increased by +0.2 mmHg in the DRSP group 
and by +2.9 mmHg in the DSG group. 
The mean body weight for almost all cycles during treatment with DRSP was virtually unchanged from baseline 
(mean change on cycle 13: +0.03 kg). During treatment with DSG, the mean body weight for all cycles was 
slightly elevated vs. baseline (mean change on cycle 13: +0.54 kg).  
The overall levels of the safety laboratory values before and after treatment did not suggest an influence of the 
study preparations. The incidence of laboratory abnormalities was low and not appreciably different in the 
baseline and the posttreatment examinations. Individual deviations from normal laboratory ranges were transient, 
generally small and not clinically relevant. 
Table 3: Carbohydrate profile, AUCs (0-3 h) (mean ± SD) 
 Unit Baseline Cycle 6 Cycle 13 Absolute change baseline 
to cycle 13 
p-valuea
  DRSP DSG DRSP DSG DRSP DSG DRSP DSG  
Glucose mg/dL*h 287 ± 49 299 ± 44 319 ±32 312 ± 52 316 ± 52 321 ± 45 28.7 ± 48.6 22.2 ± 39.6 0.57 
Insulin µU/mL*h 116 ± 51 117 ± 53 158 ± 66 154 ± 60 130 ± 55 125 ± 58 14.3 ± 67.5 7.8 ±61.8 0.62 
C-peptide µmol/L*h 6.0 ± 1.3 5.9 ± 1.2 6.7 ± 1.5 6.5 ± 1.4 6.2 ± 1.7 5.9 ± 1.4 0.22 ± 1.7 -0.07 ± 1.5 0.57 
Free fatty acids µEq/L*h 649 ± 223 630 ± 190 676 ± 206 735 ± 208 607 ± 165 679 ± 172 -42.4 ± 222 48.9 ± 214 0.24 
a Test was performed on the natural logarithm of the AUCs. 
4. DISCUSSION 
In this randomized study, we investigated the influence of the new OC Yasmin containing 30 µg EE and 3 mg 
DRSP on carbohydrate metabolism variables during 13 cycles of treatment in healthy female volunteers in 
comparison to the marketed OC Marvelon containing 30 µg EE and 150 µg DSG as a reference. 
Several studies [2,21,22] have shown that Marvelon has only a small influence on carbohydrate metabolism. 
Yasmin contains the progestin DRSP, a 17-α-spirolactone derivative with a unique pharmacological profile that 
combines potent progestogenic with antiandrogenic and the unique antimin-eralocorticoid activity. In this study, 
we investigated the impact of the novel combination on carbohydrate metabolism to proof the safety of the 
preparation [23]. 
Our data show that a 1-year treatment with the combinations of EE with DSG or DRSP does not affect the levels 
of glucose and insulin, whereas the levels of C-peptide and free fatty acids were slightly decreased. Our data for 
the reference preparation confirm the results of Si et al. [22] and Crook et al. [2]. The data for the combination of 
EE with DRSP are in accordance with preliminary results from Oelkers et al. [16]. None of the preparations 
caused any major changes of the fasting blood levels of the carbohydrate variables, even during long-term use. 
The data are not suggestive of a negative influence of the preparations regarding the cardiovascular disease risk 
of the users [24]. Fasting levels of plasma C-peptide and the molar ratio C-peptide:immuno-reactive insulin (data 
not shown) remained unchanged throughout the entire study in both treatment groups. This observation, which 
was made earlier for the combination of EE with DSG [2], suggests that basal, fasting insulin secretion by the 
pancreas is almost unchanged during 1-year use of these preparations. 
OCs, particularly those with high doses of potent 19-nortestosterone derivatives may cause a state of insulin 
resistance, as suggested by a slight reduction of oral glucose tolerance in the presence of slight hyperinsulinism 
[25-28]. In agreement with this general observation, the present study showed slightly elevated plasma glucose 
and insulin AUCs during the oral glucose tolerance tests after 1 year of use of the preparation, compared to 
baseline. However, all blood glucose and insulin levels remained within normal ranges and well below the 
threshold of impaired glucose tolerance. Differences between both treatments were not statistically significant. 
Our data confirm previous results for the combinations of EE with DRSP [16] or DSG [2]. A slight decrease in 
glucose tolerance which was similar in magnitude to the decrease observed in this study was found in a study 
with a combination of the same dose of DSG (150 µg) with a lower dose of 20 µg EE [23,29]. C-peptide AUCs 
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are a measure of pancreatic insulin secretion. In the present study, the C-peptide AUCs remained virtually 
unaffected in both groups during 13 treatment cycles, indicating no significant changes in insulin secretion and 
thus probably no deterioration of insulin sensitivity. In addition, it is emphasized that no abnormal values for 
blood glucose, plasma insulin or C-peptide were recorded in the postglucose load period, indicating that there 
was no shift towards an impaired glucose tolerance [20] for any of the volunteers during this study. The results 
for the AUCs of free fatty acids during the oGTTs were almost unchanged and, in contrast to the observation of 
Singh and Nattrass [30], do not point to any abnormality of free fatty acids responsiveness to the antilipolytic 
action of insulin. 
As mentioned above, all blood glucose and insulin levels measured during the oGTTs remained within normal 
ranges, despite a slight increase of the AUCs (0-3 h) of both variables after 1 year of treatment. None of the 
fasting or postglucose load values of blood glucose and plasma insulin reached the level of impaired glucose 
tolerance during use of either preparation. During the physiological menstrual cycle of untreated women, slight 
decreases in glucose tolerance and insulin sensitivity have been described for the luteal phase when both 
estradiol and progesterone are secreted, in comparison to the follicular phase when only estradiol is secreted 
[31]. The changes observed in carbohydrate metabolism during the use of low-dose OCs in this study were 
similar in magnitude to the changes occurring during the physiological menstrual cycle and not sufficient to 
induce an increase in the incidence of diabetes mellitus [32]. This is in contrast to the changes induced by older, 
high dose OCs, which may slightly deteriorate glucose tolerance and cause hyperinsulinemia [33]. 
Godsland [28] summarized observations (also by our group [23,34]) of progestogen-induced variations in plasma 
insulin half-life, presumably related to alterations in hepatic clearance of insulin. In the present study, no obvious 
changes in insulin half-life were observed. The modest increase in insulin AUC was apparently closely related to 
a slight increase in pancreatic beta cell function, as reflected by a very small increase in C-peptide levels. 
In accordance with the findings of other groups, both preparations were well tolerated and equally efficacious in 
terms of contraception and cycle control [14,15]. Compared to baseline, the mean body weight during treatment 
with the DRSP combination was slightly decreased in most cycles, while it was slightly increased vs. baseline in 
all cycles during treatment with the DSG combination. The combination with DRSP had less impact on blood 
pressure than the combination with DSG confirming the findings of previous publications [14,16]. The favorable 
influence of the combination with DRSP on body weight and blood pressure is presumably due to the 
antimineralocorticoid effect of DRSP. 
In conclusion, Yasmin, a low-dose OC containing EE and the novel progestogen DRSP, as well as the reference 
Marvelon, containing the same EE dose and DSG as progestogen had little impact on variables of carbohydrate 
metabolism after 13 treatment cycles. Observed changes were small and not suggestive of a clinically 
meaningful deterioration of carbohydrate metabolism or an increase in risk for cardiovascular disease. 
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